BioPharma Credit logo

BPCR - BioPharma Credit Share Price

$1.01 -0.0  -0.1%

Last Trade - 8:10am

Sector
Financials
Size
Mid Cap
Market Cap £1.06bn
Enterprise Value £837.3m
Revenue £115.1m
Position in Universe 377th / 1819
Bullish
Bearish
Unlock BPCR Revenue
Momentum
Relative Strength (%)
1m +4.75%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.16%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 39.3 97.3 150.9 +95.9%
+71.6 +24.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Biopharma Credit PLC revenues increased 55% to $150.9M. Net income increased 74% to $122.3M. Revenues reflect Investment income increase of 40% to $128.9M, Other income increase from $4.6M to $13.4M, FV Adjustments of Financial Investments increase from $648K to $8.6M. Net income benefited from Public relations fees decrease of 17% to $204K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BPCR
Graphical History

Revenue

BPCR Revenue Unlock BPCR Revenue

Net Income

BPCR Net Income Unlock BPCR Revenue

Normalised EPS

BPCR Normalised EPS Unlock BPCR Revenue

PE Ratio Range

BPCR PE Ratio Range Unlock BPCR Revenue

Dividend Yield Range

BPCR Dividend Yield Range Unlock BPCR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BPCR EPS Forecasts Unlock BPCR Revenue
Profile Summary

BioPharma Credit Plc is a closed-ended investment company. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company may acquire debt assets from a company operating in the life sciences industry or an entity other than a life sciences company, which directly or indirectly holds an interest in royalty rights to certain products, including any investment vehicle or special purpose vehicle. The Company's un-invested capital may be invested in cash instruments or bank deposits for cash management purposes. The Company may, from time to time, enter into such hedging or other derivative arrangements. The Company's investment manager is Pharmakon Advisors L.P.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated October 24, 2016
Public Since March 27, 2017
No. of Shareholders: n/a
No. of Employees: n/a
Sector Financials
Industry Collective Investments
Index
Exchange London Stock Exchange (Full)
Shares in Issue 1,373,872,373
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BPCR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BPCR
Upcoming Events for BPCR
Frequently Asked Questions for BioPharma Credit
What is the BioPharma Credit share price?

As of 8:10am, shares in BioPharma Credit are trading at $1.01, giving the company a market capitalisation of £1.06bn. This share price information is delayed by 15 minutes.

How has the BioPharma Credit share price performed this year?

Shares in BioPharma Credit are currently trading at $1.01 and the price has moved by -0.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioPharma Credit price has moved by 16.47% over the past year.

What are the analyst and broker recommendations for BioPharma Credit?

Of the analysts with advisory recommendations for BioPharma Credit, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioPharma Credit is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioPharma Credit next release its financial results?

BioPharma Credit is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the BioPharma Credit dividend yield?

The BioPharma Credit dividend yield is 6.9% based on the trailing twelve month period.

Does BioPharma Credit pay a dividend?

Last year, BioPharma Credit paid a total dividend of 0.07, and it currently has a trailing dividend yield of 6.9%. Looking ahead, BioPharma Credit has not announced an ex-dividend date yet.

When does BioPharma Credit next pay dividends?

BioPharma Credit has yet to annouce their ex-dividend date. The historic dividend yield on BioPharma Credit shares is currently 6.9%.

How do I buy BioPharma Credit shares?

To buy shares in BioPharma Credit you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioPharma Credit?

Shares in BioPharma Credit are currently trading at $1.01, giving the company a market capitalisation of £1.06bn.

Where are BioPharma Credit shares listed? Where are BioPharma Credit shares listed?

Here are the trading details for BioPharma Credit:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: BPCR
What kind of share is BioPharma Credit?

Based on an overall assessment of its quality, value and momentum, BioPharma Credit is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioPharma Credit share price forecast 2020?

We were not able to load any forecast data for BioPharma Credit.

How can I tell whether the BioPharma Credit share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioPharma Credit. Over the past six months, the relative strength of its shares against the market has been 26.85%. At the current price of $1.01, shares in BioPharma Credit are trading at 3.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioPharma Credit PE Ratio?

The BioPharma Credit PE ratio based on its reported earnings over the past 12 months is 11.48. The shares are currently trading at $1.01.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of BioPharma Credit?

BioPharma Credit's management team is headed by:

Jeremy Sillem - CHM
Duncan Budge - DRC
Colin Bond - DRC
Harry Hyman - DRC
Stephanie Leouzon - NED
Who are the major shareholders of BioPharma Credit?

Here are the top five shareholders of BioPharma Credit based on the size of their shareholding:

Newton Investment Management Ltd. Investment Advisor
Percentage owned: 10.02% (137.6m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 9.97% (137.0m shares)
Quilter Investors Limited Investment Advisor
Percentage owned: 6.41% (88.0m shares)
Invesco High Income Fund UK Mutual Fund
Percentage owned: 5.59% (76.8m shares)
Legorreta (Pablo G) Individual Investor
Percentage owned: 5.59% (76.7m shares)
Similar to BPCR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.